In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

New Delhi: Sun Pharma Labs has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

A new study is seeking to harness the potential of weight-loss drugs without some of the unwelcome side-effects, in a £1.2 ...

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public debate.

Centers for Disease Control and Prevention (the "CDC") reported 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl Mazindol ER potentially ...

This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists ... specific genetic mechanisms may drive diabetes development, as ...